S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

-$1.37 EPS Expected for Kodiak Sciences Inc. (NASDAQ:KOD) This Quarter

Friday, January 14, 2022 | MarketBeat

Equities analysts expect Kodiak Sciences Inc. (NASDAQ:KOD) to post earnings per share of ($1.37) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kodiak Sciences' earnings, with estimates ranging from ($1.37) to ($1.36). Kodiak Sciences posted earnings of ($0.97) per share during the same quarter last year, which would suggest a negative year over year growth rate of 41.2%. The company is scheduled to report its next quarterly earnings results on Monday, March 7th.

On average, analysts expect that Kodiak Sciences will report full year earnings of ($4.59) per share for the current year, with EPS estimates ranging from ($4.74) to ($4.16). For the next financial year, analysts expect that the company will post earnings of ($6.45) per share, with EPS estimates ranging from ($8.52) to ($4.70). Zacks Investment Research's earnings per share averages are a mean average based on a survey of analysts that follow Kodiak Sciences.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Tuesday, November 9th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.16) by ($0.14).

A number of research firms recently commented on KOD. Citigroup boosted their price target on Kodiak Sciences from $103.00 to $114.00 and gave the stock a "neutral" rating in a report on Thursday, November 11th. BMO Capital Markets boosted their price target on Kodiak Sciences from $104.00 to $114.00 and gave the stock a "market perform" rating in a report on Friday, November 12th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $128.63.

Shares of NASDAQ:KOD traded up $2.36 during mid-day trading on Friday, reaching $65.18. 30,257 shares of the company traded hands, compared to its average volume of 242,442. The company's 50 day moving average price is $91.65 and its 200-day moving average price is $95.25. The firm has a market cap of $3.37 billion, a PE ratio of -15.05 and a beta of 1.40. Kodiak Sciences has a 52 week low of $61.37 and a 52 week high of $171.21.

In related news, insider John A. Borgeson sold 876 shares of the stock in a transaction on Wednesday, November 10th. The stock was sold at an average price of $115.42, for a total transaction of $101,107.92. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jason Ehrlich sold 6,950 shares of the stock in a transaction on Monday, November 22nd. The shares were sold at an average price of $99.15, for a total value of $689,092.50. The disclosure for this sale can be found here. Insiders have sold a total of 21,726 shares of company stock worth $2,175,822 over the last ninety days. Insiders own 39.70% of the company's stock.

A number of large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its holdings in Kodiak Sciences by 8.0% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 7,413,150 shares of the company's stock valued at $689,423,000 after buying an additional 551,429 shares during the period. Wellington Management Group LLP grew its position in Kodiak Sciences by 2.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,189,914 shares of the company's stock valued at $594,108,000 after acquiring an additional 144,539 shares during the last quarter. Vanguard Group Inc. grew its position in Kodiak Sciences by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 2,988,161 shares of the company's stock valued at $277,899,000 after acquiring an additional 50,665 shares during the last quarter. State Street Corp grew its position in Kodiak Sciences by 17.9% in the 2nd quarter. State Street Corp now owns 1,184,757 shares of the company's stock valued at $110,182,000 after acquiring an additional 179,820 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Kodiak Sciences by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 586,590 shares of the company's stock valued at $56,300,000 after acquiring an additional 10,327 shares during the last quarter. Institutional investors own 87.00% of the company's stock.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical-stage biopharmaceutical company. The firm engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD.

See Also: Equal Weight Rating

Get a free copy of the Zacks research report on Kodiak Sciences (KOD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kodiak Sciences (NASDAQ:KOD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Kodiak Sciences right now?

Before you consider Kodiak Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.

While Kodiak Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.